Can I read Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patients on EtoBox?

Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patients by Philippe Minodier; Karine Retornaz; Alexia Horelt; Jean-Marc Garnier is a Medicine article available to read on EtoBox.

What is Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patients about?

## Abstract The leishmaniases are protozoan diseases caused by __Leishmania__ parasites. The first‐line treatment of its visceral forms is pentavalent antimony (meglumine antimoniate or sodium stibogluconate), but toxicity is frequent with this drug. Moreover antimony unresponsiveness is increasing in __Leishmania infantum__ and __L. donovani__ foci, both in immunocompetent and in immunosuppressed patients. Amphotericin B is a polyene macrolide antibiotic that binds to sterols in cell membranes. It is the most active antileishmanial agent in use. Its infusion‐related and renal toxicity may be reduced by lipid‐based delivery. Liposomal amphotericin B (AmBisome^®^; Gilead Science, Paris, France) seems to be less toxic than other amphotericin B lipid formulations (Amphocil^®^; Liposome Technology Inc., Menlo Park, CA, USA, Amphotec^®^; Ben Venue Laboratories Inc., Bedford, OH, USA). Optimal drug regimens of AmBisome^®^ vary from one geographical area to another. In the Mediterranean Basin, a total dose of 18 mg/kg (3 mg/kg on days 1–5 and 3 mg/kg on day 10) could be used as first‐line treatment of visceral leishmaniasis in immunocompetent patients. In immunocompromised patients, espec

Who reads Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patients?

Author

Philippe Minodier; Karine Retornaz; Alexia Horelt; Jean-Marc Garnier

Publisher

John Wiley and Sons; Wiley (Blackwell Publishing); Blackwell Publishing Inc.; Wiley (ISSN 0767-3981)

Published

2003

Language

EN

Field

Medicine (Health Sciences)